Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

DermTech, Inc. DMTKQ

Healthcare  —  Diagnostics & Research
0.00 0.00 NaN as of 13 Aug
Market cap
$3.3M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

DermTech, Inc. (DMTKQ) Business Profile

Updated before January 2025

Company Overview

DermTech, Inc. (DMTKQ) is a pioneering biotechnology company specializing in precision dermatology. Founded in 2010 and headquartered in San Diego, California, DermTech focuses on non-invasive genomic testing for skin health, particularly in the early detection of skin cancer. The company was co-founded by Dr. George Schwartz and Dr. John Dobak, who envisioned a revolutionary approach to dermatological diagnostics. Dr. Dobak currently serves as the CEO, bringing decades of experience in biotechnology and healthcare innovation. DermTech’s mission is to transform dermatology by leveraging advanced genomics and AI-driven solutions to improve patient outcomes and reduce healthcare costs.

Core Business Segments

Genomic Testing for Skin Cancer

DermTech’s flagship product is the DermTech Melanoma Test (DMT), a non-invasive genomic test designed to detect melanoma at its earliest stages. The test uses a patented adhesive patch to collect skin samples, eliminating the need for surgical biopsies. This innovative approach provides a more accurate, patient-friendly, and cost-effective alternative to traditional diagnostic methods.

Research and Development Services

In addition to its commercial products, DermTech offers genomic testing services to pharmaceutical companies and academic institutions. These services support the development of new dermatological treatments and enhance the understanding of skin-related diseases.

AI-Driven Dermatology Solutions

DermTech is also investing in artificial intelligence to develop predictive analytics tools for dermatology. These tools aim to assist healthcare providers in diagnosing and managing skin conditions more effectively.

Business Model

DermTech operates on a hybrid business model that combines product sales, service contracts, and licensing agreements. Revenue is primarily generated through the sale of its genomic tests to dermatologists, healthcare providers, and laboratories. The company also earns income from research collaborations and licensing its proprietary technology to third parties. By integrating cutting-edge genomics with AI-driven analytics, DermTech aims to create a comprehensive ecosystem for precision dermatology.

Strategic Direction

DermTech is committed to expanding its product portfolio and market reach. The company plans to:

  • Enhance Product Offerings: Develop new genomic tests for other skin conditions, such as psoriasis and eczema.
  • Global Expansion: Enter international markets, particularly in Europe and Asia, where demand for advanced dermatological diagnostics is growing.
  • Sustainability Goals: Implement eco-friendly practices in its manufacturing and supply chain operations.
  • Technological Innovation: Invest in AI and machine learning to improve diagnostic accuracy and patient outcomes.

Competitive Landscape

DermTech operates in a highly competitive market that includes traditional diagnostic companies and emerging biotech firms. Key competitors include:

  • Castle Biosciences: Specializes in genomic testing for skin cancer and other diseases.
  • Myriad Genetics: Offers a range of genetic testing services, including dermatology-focused solutions.
  • Exact Sciences: Known for its non-invasive cancer screening tests.

Despite the competition, DermTech differentiates itself through its non-invasive approach and focus on precision dermatology.

Risk Factors

DermTech faces several risks that could impact its business:

  • Market Dependence: Reliance on the success of its melanoma test for revenue generation.
  • Regulatory Challenges: Compliance with stringent healthcare regulations in different markets.
  • Supply Chain Disruptions: Potential delays in the production and distribution of its products.
  • Technological Risks: The need to continuously innovate to stay ahead of competitors.

Recent Developments

In 2023, DermTech launched an upgraded version of its melanoma test, featuring enhanced genomic markers for improved accuracy. The company also announced a strategic partnership with a leading AI firm to develop predictive analytics tools for dermatology. Additionally, DermTech expanded its operations to Europe, establishing a regional headquarters in Germany.

Investment Considerations

Strengths

  • Innovative Technology: Non-invasive genomic testing sets DermTech apart from traditional diagnostic methods.
  • Growing Market: Increasing awareness of skin cancer and demand for early detection solutions.
  • Strong Leadership: Experienced management team with a proven track record in biotechnology.

Risks

  • High Competition: Intense rivalry from established players and new entrants.
  • Regulatory Hurdles: Potential delays in product approvals.
  • Financial Uncertainty: Dependence on external funding for R&D and market expansion.

Conclusion

DermTech, Inc. is at the forefront of precision dermatology, offering innovative solutions that address critical gaps in skin cancer detection and management. With a strong focus on technology and patient-centric care, the company is well-positioned for growth in a rapidly evolving market. However, investors should carefully consider the associated risks before making investment decisions.